Archive
Articles
Cited research, honest evidence tiers, and zero marketing spin.
research
GLP-1 Combinations: What Asian T2D Data Show
Ian Gauntt, RN BSN · Sep 18, 2026 · 12 min
A 2025 review examines GLP-1 combinations with basal insulin in Asian adults with type 2 diabetes—what the data show on efficacy, safety, and dosing.
decision-framework
FDA uses AI to flag peptide vendors labeled ‘research use only’
Ian Gauntt, RN BSN · Sep 18, 2026 · 3 min
FDA deploys AI surveillance to flag peptide vendors whose “research use only” labels mask human‑use claims, prompting warning letters and enforcement actions.
pharmacokinetics
Oral peptide bioavailability: what research shows
Ian Gauntt, RN BSN · Sep 17, 2026 · 14 min
Oral peptide bioavailability is notoriously low. Recent preclinical and formulation research explains why—and what scientists are testing to fix it.
guides
Exendin-4 Bone Loss: What New Research Shows
Ian Gauntt, RN BSN · Sep 16, 2026 · 12 min
A 2025 preclinical study tested local exendin-4 bone loss prevention around implants. Here is what the animal data found and what remains unknown.
fundamentals
IL-31 and itch: what atopic dermatitis research shows
Ian Gauntt, RN BSN · Sep 15, 2026 · 13 min
IL-31 and itch drive the misery of atopic dermatitis. Here is what preclinical and clinical research reveals about the neuroimmune pathway and nemolizumab.
decision-framework
Emideltide (DSIP) Falls Short in FDA Compounding Vote
Ian Gauntt, RN BSN · Sep 15, 2026 · 2 min
FDA advisory panel rejected emideltide (DSIP) from the 503A compounding list citing safety, route mismatch, and poor characterization. Highlights evidence thresholds.
decision-framework
Peptide fertility strategies: what research shows
Ian Gauntt, RN BSN · Sep 12, 2026 · 13 min
Peptide fertility strategies are emerging to counter TRT-induced suppression. Here's what a 2025 narrative review found in preclinical and clinical data.
decision-framework
BMJ flags peptide safety and conflict concerns
Ian Gauntt, RN BSN · Sep 12, 2026 · 2 min
BMJ reports FDA scientists worry about carcinogenicity, organ toxicity, addiction risks in experimental peptides, and advisory panel industry ties that may skew regulation.
research
Tirzepatide: What Sleep Apnea Research Shows
Ian Gauntt, RN BSN · Sep 11, 2026 · 13 min
New post-hoc analyses of SURMOUNT-OSA examine tirzepatide and sleep apnea outcomes by baseline characteristics. Here is what the clinical data actually found.
pharmacokinetics
Bioavailability Barriers: Why Peptides Fail
Ian Gauntt, RN BSN · Sep 10, 2026 · 14 min
Bioavailability barriers stop most therapeutic peptides from reaching targets. Preclinical research reveals why—and what scientists are testing.
guides
Peptide-coupled red blood cells: MS research
Ian Gauntt, RN BSN · Sep 9, 2026 · 13 min
A 2025 PNAS study tested peptide-coupled red blood cells in multiple sclerosis models. Here is what the preclinical data show about tolerance induction.
research
Gene‑encoded micropeptides as actionable targets
Ian Gauntt, RN BSN · Sep 9, 2026 · 2 min
Review uncovers gene‑encoded micropeptides from sORFs in lncRNAs, circRNAs and UTRs as functional regulators and emerging therapeutic targets in cancer and immunity
fundamentals
Exendin-4 brain injury: what research shows
Ian Gauntt, RN BSN · Sep 8, 2026 · 12 min
A 2025 preclinical study tested exendin-4 brain injury protection in a fetal inflammatory model. Here is what the data found and what remains unknown.
fundamentals
Antidiabetic Drugs: What Parkinson's Research Shows
Ian Gauntt, RN BSN · Sep 6, 2026 · 12 min
A Bayesian meta-analysis compared antidiabetic drugs for Parkinson's disease risk. Here's what the preclinical and clinical evidence actually shows.
pharmacokinetics
BPC-157 Pharmacokinetics: What Research Shows
Ian Gauntt, RN BSN · Sep 3, 2026 · 13 min
BPC-157 pharmacokinetics pose real formulation challenges. Here is what preclinical and early translational research shows about this investigational peptide.
guides
Oral GnRH Antagonists: What Fibroid Research Shows
Ian Gauntt, RN BSN · Sep 2, 2026 · 11 min
Oral GnRH antagonists are approved for uterine fibroids. See what clinical evidence shows about how they work and what remains uncertain.
fundamentals
Diabetic Heart Damage: What New Studies Show
Ian Gauntt, RN BSN · Sep 1, 2026 · 12 min
Diabetic heart damage is the focus of new rat studies probing insulin signaling and post-PCI failure. Here is what the preclinical data found.
decision-framework
Cagrisema Weight Loss: What RCT Data Show
Ian Gauntt, RN BSN · Aug 31, 2026 · 13 min
A 2025 meta-analysis pooled RCT data on cagrisema weight loss. Here is what the evidence found and what remains uncertain.
fundamentals
Exendin-4: What Anxiety Research Shows
Ian Gauntt, RN BSN · Aug 30, 2026 · 14 min
Exendin-4 reduced anxiety-like behaviors in stressed mice by acting on GLP-1 receptors in the brain. Here is what the preclinical research actually found.
research
Tirzepatide: Blood Pressure and Cardiometabolic Data
Ian Gauntt, RN BSN · Aug 28, 2026 · 13 min
New meta-analyses examine tirzepatide blood pressure, weight, and cardiovascular risk markers. Here's what the studies found.
pharmacokinetics
Antimicrobial Peptides: How Delivery Shapes Efficacy
Ian Gauntt, RN BSN · Aug 27, 2026 · 16 min
Antimicrobial peptides show promise against drug-resistant bacteria, but delivery barriers limit their reach. Here's what preclinical research reveals.
guides
Oral GLP-1 Agonists: What Phase II Data Show
Ian Gauntt, RN BSN · Aug 26, 2026 · 13 min
A phase II trial of oral GLP-1 agonists found significant weight loss without injections. Here is what the VCT220 data show and what questions remain.
fundamentals
PTH 1-34: What Periodontitis Research Shows
Ian Gauntt, RN BSN · Aug 25, 2026 · 11 min
PTH 1-34 reduced bone loss and shifted immune balance in a preclinical periodontitis model. Here is what the research actually found and what remains unknown.
decision-framework
Real-World Drug Data: What Studies Actually Show
Ian Gauntt, RN BSN · Aug 24, 2026 · 14 min
Real-world drug data from five 2025 studies reveals how semaglutide, lecanemab, and upadacitinib perform outside controlled trials—and what the gaps mean.
fundamentals
GLP-1 Medicines: Beyond Weight Loss
Ian Gauntt, RN BSN · Aug 23, 2026 · 12 min
GLP-1 medicines do more than cut calories. Explore what preclinical and clinical research reveals about their weight-loss-independent actions.
decision-framework
GLP-1 Agonists: What New Research Shows
Ian Gauntt, RN BSN · Aug 22, 2026 · 14 min
GLP-1 agonists are showing up in surprising clinical contexts. Here's what new research shows about epilepsy, stoma care, and heart signals.
research
Romiplostim: What Research Shows
Ian Gauntt, RN BSN · Aug 21, 2026 · 14 min
Romiplostim research in immune thrombocytopenia: what a 2025 systematic review and meta-analysis found about efficacy and safety signals.
pharmacokinetics
Peptide Delivery: How Stimuli-Responsive Systems Work
Ian Gauntt, RN BSN · Aug 20, 2026 · 13 min
Explore how stimuli-responsive peptide delivery systems control release timing, reduce burst effects, and improve pharmacokinetics in preclinical research.
guides
Anti-CGRP Antibodies: What Research Shows
Ian Gauntt, RN BSN · Aug 19, 2026 · 13 min
Anti-CGRP antibodies are reshaping migraine care. See what a 2025 retrospective cohort study found about treatment persistence and adherence.
fundamentals
GLP-1 Medicines: Beyond Weight Loss
Ian Gauntt, RN BSN · Aug 18, 2026 · 12 min
GLP-1 medicines do more than shrink waistlines. Explore the weight-loss-independent actions researchers are studying in heart, liver, and immune health.
decision-framework
GLP-1 Agonists: What Epilepsy Research Shows
Ian Gauntt, RN BSN · Aug 17, 2026 · 15 min
GLP-1 agonists meet epilepsy: what a 2025 clinical study found about safety and efficacy in adults with obesity, type 2 diabetes, and seizure disorders.
fundamentals
Hirudin: What Research Shows
Ian Gauntt, RN BSN · Aug 16, 2026 · 14 min
Discover what preclinical studies reveal about hirudin, a natural peptide, and how it may protect kidneys from uric acid-induced injury via NF-κB signaling.
decision-framework
GLP-1 Analogues: What High-Output Stoma Research Shows
Ian Gauntt, RN BSN · Aug 15, 2026 · 11 min
GLP-1 analogues are being studied for high-output stomas. Here's what a 2025 narrative review found about mechanisms, evidence, and open questions.
research
New Peptides: What Research Shows
Ian Gauntt, RN BSN · Aug 14, 2026 · 13 min
New peptides are reshaping research in 2025. Explore what clinical studies show about LTI-03, zenagamtide, eptinezumab, and more.
pharmacokinetics
Burst Release: Why Peptide Timing Matters
Ian Gauntt, RN BSN · Aug 13, 2026 · 16 min
Burst release can undermine peptide therapies. Learn what preclinical research reveals about controlling drug timing in modern delivery systems.
guides
Inhaled Peptides: What IPF Research Shows
Ian Gauntt, RN BSN · Aug 12, 2026 · 12 min
Inhaled peptides for IPF are entering clinical trials. Here's what early research on LTI-03 and lung biology actually found, explained clearly.
fundamentals
Hirudin: What Research Shows
Ian Gauntt, RN BSN · Aug 11, 2026 · 12 min
Discover what preclinical studies reveal about hirudin, a natural peptide, and how it may protect kidneys from uric acid injury via NF-κB signaling.
decision-framework
GLP-1 Analogues: What Research Shows for High-Output Stoma
Ian Gauntt, RN BSN · Aug 10, 2026 · 12 min
GLP-1 analogues are being studied for high-output stoma management. Here's what the latest narrative review evidence actually shows.
fundamentals
N-Methylation: How It Shapes Peptides
Ian Gauntt, RN BSN · Aug 9, 2026 · 12 min
Learn how backbone N-methylation reshapes peptide structure and boosts protein binding, based on preclinical chemistry research. Fundamentals explained.
decision-framework
Decision Frameworks: Reading New Drug Data
Ian Gauntt, RN BSN · Aug 8, 2026 · 13 min
Learn decision frameworks for reading new drug data across cancer, metabolic, and neurological research—without falling for hype or missing real signals.
research
Semaglutide & Liver Disease: What Studies Show
Ian Gauntt, RN BSN · Aug 7, 2026 · 12 min
New meta-analysis data on semaglutide and metabolic liver disease explained. What placebo-controlled trials found—and what remains unknown.
pharmacokinetics
Peptide Delivery: How Nanotech Solves It
Ian Gauntt, RN BSN · Aug 6, 2026 · 14 min
Peptide delivery is transformed by nanoarchitectures and stimuli-responsive systems. Explore what preclinical research reveals about bioavailability challenges.
guides
Peptide Hydrogels: How They Heal Eyes
Ian Gauntt, RN BSN · Aug 5, 2026 · 10 min
Peptide hydrogels may help repair stubborn corneal wounds. Learn what preclinical research reveals about self-assembling biomimetic peptide hydrogels.
fundamentals
N-Methylation: How It Shapes Peptides
Ian Gauntt, RN BSN · Aug 4, 2026 · 12 min
Learn how backbone N-methylation reshapes peptide structure and improves protein binding, based on preclinical chemistry research.
decision-framework
Decision Frameworks: Reading New Drug Data
Ian Gauntt, RN BSN · Aug 3, 2026 · 16 min
Decision frameworks help you understand what recent clinical trials on peptides and drugs actually found—and what the evidence really means for research.
fundamentals
GLP-1 Peptides: The Obesity-Inflammation Link
Ian Gauntt, RN BSN · Aug 2, 2026 · 12 min
GLP-1 receptor agonists may connect obesity and inflammation in arthritis and psoriasis. Here's what the latest research actually found.
decision-framework
Treatment Trade-offs: How to Weigh Your Options
Ian Gauntt, RN BSN · Aug 1, 2026 · 15 min
Explore treatment trade-offs across six therapy areas—from Cushing's syndrome to migraine—using real study findings to guide smarter conversations with your doctor.
research
Semaglutide: What Research Shows
Ian Gauntt, RN BSN · Jul 31, 2026 · 12 min
What does recent research say about semaglutide? Explore findings on fatty liver, diabetes prevention, and PCOS from clinical and meta-analysis studies.
pharmacokinetics
Peptide Pharmacokinetics: Why Delivery Matters
Ian Gauntt, RN BSN · Jul 30, 2026 · 14 min
Peptide pharmacokinetics shape how well these molecules reach their targets. Learn what preclinical research reveals about modern delivery strategies.
guides
GIPR Agonism: How Brain Regions Control Hunger
Ian Gauntt, RN BSN · Jul 29, 2026 · 11 min
New animal research maps the brain regions behind GIPR agonism and food intake regulation. Here's what the science actually found.
fundamentals
GLP-1 Agonists: The Obesity-Inflammation Link
Ian Gauntt, RN BSN · Jul 28, 2026 · 12 min
GLP-1 agonists may bridge obesity and inflammation in arthritis and psoriasis. Explore what early research says about this emerging connection.
decision-framework
Treatment Trade-offs: How to Weigh New Data
Ian Gauntt, RN BSN · Jul 27, 2026 · 15 min
Treatment trade-offs explained: what recent clinical studies reveal about efficacy, safety, and decision frameworks for emerging therapies.
decision-framework
Should You Use Peptides? A Decision Framework
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Skip the hype. A structured framework for evaluating whether a given peptide makes sense — evidence tier, sourcing, regulatory status, and risk.
fundamentals
Peptides vs Proteins vs Amino Acids: Size & Function
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Chain length isn't trivia — it dictates synthesis, targeting, and clearance. The practical breakdown of amino acids vs peptides vs proteins.
pharmacokinetics
Peptide Pharmacokinetics: Absorption & Half-Life
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Why oral bioavailability is often under 1%, why parenteral is the default, and how half-life engineering changes the dosing equation. The PK essentials.
fundamentals
A Century of Peptide Drugs: The Timeline
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Insulin to SPPS to recombinant production to GLP-1s. The key milestones that turned peptides into one of pharma's fastest-growing categories.
fundamentals
The Peptide Boom: What's Driving the Surge
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
GLP-1 revenue, a maturing pipeline, and the longevity market. A clear-eyed look at the forces behind the peptide surge — and what's signal vs. hype.
fundamentals
The Peptide Bond: Formation & Geometry
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Condensation reaction, partial double-bond character, planar rigidity, N-to-C directionality. The structural fundamentals that govern every peptide.
fundamentals
Bioactive Peptides by Function: Classification
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Antimicrobial, antihypertensive, antioxidant, immunomodulatory — a functional map of bioactive peptides and what determines a sequence's class.
research
Retatrutide: What the Trials Actually Show
Ian Gauntt, RN BSN · Jul 5, 2026 · 2 min
The triple-agonist everyone's whispering about has real, published human RCTs behind it — up to 24.2% weight loss at 48 weeks and dramatic liver-fat drops. Here's what the data say, and what it still can't tell you.
guides
Evidence Tiers, Explained: What Our Badges Actually Mean
Ian Gauntt, RN BSN · Jun 27, 2026 · 2 min
Every peptide on this site wears an evidence badge — human-RCT, human, preclinical, or anecdotal. Here's exactly what each one means, and why we refuse to let a rat study cosplay as a clinical trial.
guides
Peptides 101: A Field Guide for People Who Actually Read the Studies
Ian Gauntt, RN BSN · Jun 20, 2026 · 2 min
A no-hype orientation to research peptides — what they are, why the evidence is all over the map, and how to tell a human trial from a rat study before you believe a single claim.